Sumary of SARS-CoV-2 enzyme inhibitors among drugs screened for repurposing:
- In the context of the coronavirus disease 2019 (COVID-19) pandemic, with over 3.5 million deaths and counting as of June 9, 2021, the development of effective antivirals remains essential..
- This persistent need is largely due to the fact that most of the currently available vaccines target the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appears to constantly undergo rapid and critical mutations..
- A new bioRxiv* preprint describes the identification of some promising pharmaceutical compounds that could be developed as antiviral drugs against COVID-19..
- Blue Planet Studio / Shutterstock.com Background The SARS-CoV-2 genome encodes ten open reading frames (ORFs), the largest of which is ORF1ab..
- These actions are important in regulating antiviral host innate immune responses and promoting successful infection by SARS-CoV-2..
- Molecular docking studies on the top hits helped clarify how these compounds bound to the PLpro active site by different modes..
- These findings indicate potential opportunities for repurposing these drugs to help in the ongoing fight to treat patients with severe COVID-19…